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We developed cell-free implants, comprising carbodiimide crosslinked recombinant human collagen
(RHC), to enable corneal regeneration by endogenous cell recruitment, to address the worldwide
shortage of donor corneas. Patients were grafted with RHC implants. Over four years, the regenerated
neo-corneas were stably integrated without rejection, without the long immunosuppression regime
needed by donor cornea patients. There was no recruitment of inﬂammatory dendritic cells into the
implant area, whereas, even with immunosuppression, donor cornea recipients showed dendritic cell
migration into the central cornea and a rejection episode was observed. Regeneration as evidenced by
continued nerve and stromal cell repopulation occurred over the four years to approximate the micro-
architecture of healthy corneas. Histopathology of a regenerated, clear cornea from a regrafted patient
showed normal corneal architecture. Donor human cornea grafted eyes had abnormally tortuous nerves
and stromal cell death was found. Implanted patients had a 4-year average corrected visual acuity of 20/
54 and gained more than 5 Snellen lines of vision on an eye chart. The visual acuity can be improved with
more robust materials for better shape retention. Nevertheless, these RHC implants can achieve stable
regeneration and therefore, represent a potentially safe alternative to donor organ transplantation.
 2013 The Authors. Published by Elsevier Ltd. All rights reserved.1. Introduction While transplantation can cure corneal blindness, there is a severeIn 2012, the World Health Organization estimated that 285
million people worldwide are visually impaired, while 39 million
are blind [1]. Corneal blindness accounts for 5.1% of cases, with 1.5e
2 million new cases of unilateral blindness reported annually [2].collagen-based corneal im-
tient’s regenerated corneas
nerves continue to actively
cell recruitment, conﬁrming
r human corneas.
r the terms of the Creative
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Published by Elsevier Ltd. All righshortage of donor corneas [2,3]. Although two-year success rates
for corneal transplantation are 85% in developed nations like
Sweden [4], those for a developing country (e.g. South India) start
at 69% [5]. Data from the Australian Corneal Graft Registry shows
that the success rate for corneal transplantation is 73% at 5 years
and 62% at 10 years [6], which is even lower than for kidney
transplantation [7].
As an alternative to donor cornea transplantation, in Fagerholm
et al. [8], we showed the regeneration of corneal tissues and nerves
after implantation of cell-free, biointeractive corneal implants
made from 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hy-
drochloride (EDC) and N-hydroxysuccinimide (NHS) crosslinked
recombinant human collagen type III (RHCIII). These RHCIII corneal
implants were designed as simple mimics of the largely collage-
nous extracellular matrix of the cornea stroma to stimulate in situ
regeneration of pathologic corneas.
In the present study, we provide details of the RHCIII implants
and report on their four year, long-term progress within thets reserved.
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regenerated neo-corneas and the time course of the regenerative
events. We also compared the immune compatibility of such cell-
free, biointeractive implants over four years without immunosup-
pression against corneas grafted with human donor corneas by
penetrating keratoplasty, which is considered the “gold standard”
in corneal transplantation [9].
2. Materials and methods
2.1. Biosynthetic corneal implants
Implants were produced under Class 100 conditions in a cleanroom following
Good Manufacturing Practice guidelines. Clinical grade recombinant human
collagen type III (RHCIII) produced in yeast (Pichia pastoris) was purchased from
FibroGen, Inc. (San Francisco, CA), dia-ﬁltrated, freeze-dried, and reconstituted to a
10% (w/w) optically clear solution. EDC was supplied by SigmaeAldrich (St. Louis,
MO). NHS was supplied by Fluka (Buchs, Switzerland). Phosphate buffered saline
(PBS, pH 7.4) was prepared from the tablet form (Calbiochem Corp., Darmstadt,
Germany). Aliquots of 500 ml of RHCIII solution were carefully loaded into a syringe
mixing systemwe previously developed [10], to ensure that the RHCIII solution was
free of air bubbles. A predetermined quantity of cross-linker was added based on a
molar equivalent ratio of crosslinker: collagen-NH2 (collagen-NH2 denotes the
ε-amine groups on collagen molecules) of 0.4:1. After thorough mixing at 4 C, the
solution was dispensed into curved polypropylene contact lens moulds (500 mm
thick,10mmdiameter) and cured at 100% humidity at ambient temperature for 24 h.
The implants werewashed thoroughly in sterile phosphate buffered saline (PBS) and
then immersed in PBS containing 1% chloroform to maintain sterility and stored at
4 C. The EDC and NHS are not incorporated into the ﬁnal implant [11], circum-
venting the possibility of toxic breakdown products.
2.2. Characterization of implants
Quality control criteria used to determine release for patient use were visual
inspection using a zonometer to ensure smooth, defect-free inner and outer sur-
faces, and the optical properties of the implant. Brieﬂy, the refractive indices of each
fully hydrated implant equilibrated in PBS were measured using an Abbe refrac-
tometer (Model C10, VEE GEE Scientiﬁc Inc., Kirkland, Washington) at 21 C with
bromonaphthalene as the calibration agent to ensure refractive indices of 1.35. A
custom-built instrument was used to measure the light transmission of individual
samples at room temperature as compared to open beam intensity [12]. The relative
percent of light back scattered from the collimated beam by the sample was
measured with a circular array of eight photodiodes, 30 off axis. For clinical use,
only samples showing light transmission >90% were selected.
Other properties of the implants were also recorded, with all samples tested in
triplicate as we previously described [13]. The mechanical properties, tensile
strength, moduli and elongation at break, were determined with an Instron me-
chanical universal tester (Model 3342, Instron, Canton, MA) equipped with a 0.01 kN
load cell and Instron Series IX/S software. The crosshead speed was 10 mm min1
and the sampling rate was 10 points s1. Implants were not pre-stressed. Mea-
surements were taken at room temperature in a >75% humidity chamber.
Thermal stability of PBS-equilibrated hydrogel samples was determined using
differential scanning calorimetry (DSC-2C, Perkin Elmer, Waltham, MA; with Ther-
mal Analysis Software system, Instrument Specialists Inc., Spring Grove, IL). Heating
scans were recorded in the range of 8e80 C at a scan rate of 5 C min1. PBS
equilibrated samples (5e10 mg) were surface-dried with ﬁlter paper and then
hermetically sealed in aluminium pans to prevent water evaporation. A resulting
heat ﬂux vs. temperature curve was then used to calculate the denaturing tem-
perature (Td) and the enthalpy (DHd). The denaturing temperature is given by the
maximum point of the endothermic peak. Enthalpy was determined by integrating
the endothermic peak to determine the peak area. The enthalpy of transition,
DH ¼ KA, where K is the calorimetric constant and A is the area under the curve. The
calorimetric constant was pre-determined by the manufacturer.
The water content of PBS-equilibrated hydrogels was measured as follows.
Hydrogels were removed from the solution, gently blotted dry with ﬁlter paper and
immediately weighed on a microbalance to record the wet weight of the sample.
Hydrogels of known weight were then dried at room temperature under vacuum to
constant weight. The total equilibrated water content of the hydrogels (Wt) was
calculated according to the equation:
Wt ¼ ðW WoÞ=Ww  100%;
where W and Wo denote the wet and dry weights of the samples, respectively.
2.3. Clinical study design and treatment
This study was approved by the Linköping Regional Ethical Review Committee
and Swedish Medical Products Agency, registered (EudraCT no. 2006-006585-42)
and conformed to the Declaration of Helsinki. Subjects were comprised of 10
consecutive patients on the waiting list for corneal transplantation, 8 males and 2females aged 18e75 years at time of surgery, with keratoconus (9 cases) or central
scarring (1 case) [8]. They were grafted with biosynthetic implants by anterior
lamellar keratoplasty and retained using overlying sutures, as they were not sufﬁ-
ciently robust for stabilization with running sutures. An additional 9 patients with
similar corneal pathologies, 6 males and 3 females aged 40e79 years, with kera-
toconus (5 cases), endothelial decompensation (2 cases), a deep central scar (1 case)
and pseudophakic bullous keratopathy (1 case) were grafted with human donor
allograft corneas by full-thickness penetrating keratoplasty, stabilized with
peripherally located running sutures. A tenth allografted patient was excluded after
a retinal detachment occurred twomonths postoperatively. Twenty volunteers with
healthy corneas, aged 15e88 years, were examined as normal benchmarks.
2.4. Postoperative assessments
Patients were assessed at 1, 3, 6 and 9 months, and 1, 2, 3, and 4 years post-
operatively, while healthy volunteers were examined once. Examinations included
slit-lamp microscopy, corneal surface sensitivity measurement by Cochet-Bonnet
contact esthesiometry, anterior segment optical coherence tomography, and laser-
scanning in-vivo confocal microscopy.
2.5. Optical coherence tomography and topographical mapping to measure implant
stability
The stability of the implants and regenerated neo-corneas was assessed by
examining the changes in thickness and shape over time.
Anterior segment optical coherence tomography was used to monitor the
change in corneal thickness. Two-way ANOVA analysis was used with a general
linear model to compare central corneal thickness with respect to group and post-
operative time. The nonparametric ManneWhitney Rank Sum test was used where
data did not satisfy equal variance testing for the comparison of central corneal
thickness at four years in operated groups versus normal healthy corneas. Statistics
were performed using statistical software (SigmaStat 3.5 for Windows, Systat
Software Inc., Chicago IL).
To map changes in the shape, primarily of the anterior surface over time, corneal
topography analyses were performed using a Serial Orbscan II (Bausch and Lomb,
Rochester, New York) on all eyes over 4 years. Difference maps and statistics maps
were generated according to a protocol we previously developed [14].
2.6. Analysis of antigen presenting dendritic cells as an indication of immune
compatibility
In vivo confocal microscope images of the central basal and sub-epithelial areas
were analysed to identify the 2 reported morphological types of dendritic cells, the
resident antigen presenting cells of the cornea [15]. The ‘immature’ cells have
reﬂective cell bodies only, while the ‘mature’ antigen-presenting type have reﬂective
cell bodies bearing one or more short processes termed ‘dendrites’ [16,17]. In ran-
domized and coded images, the number of each type of dendritic cell per image was
manually counted and converted to a density value. Two-way ANOVA analysis was
used to compare dendritic cell density with respect to cell subtype and group.
2.7. Histopathology
One patient underwent regrafting since contact lenses required for good visual
acuity could not be ﬁtted. A clear corneal buttonwas obtained from this patient and
was routinely processed for histopathological examination. Parafﬁn-embedded
sections were stained with haematoxylin and eosin for visualization.
3. Results
3.1. Implants
Properties of the EDC/NHS crosslinked RHCIII implants are
shown in Table 1. Optical clarity exceeded that of the average hu-
man cornea, which is above 87% transmission [18]. However, the
mechanical strength was signiﬁcantly lower than that of the human
cornea [19e21], and implants were much softer, resulting in the
need for overlying sutures instead of interrupted sutures for
retention. At four years post-operation, examination by slit lamp
biomicroscopy showed that the implants were well integrated
within the corneas of all 10 patients (Fig. 1).
3.2. Implant stability
Anterior segment optical coherence tomography showed that
the shape, thickness, and border areas of engraftment of the
implanted corneas remained constant from one to four years post-
Table 1
Properties of EDC/NHS crosslinked recombinant human collagen hydrogels used as corneal implants.
Properties Transmission (%) Centre thickness (mm) Modulus (MPa) Elongation (%) Tensile strength
(MPa)
Denaturation
temperature (C)
Water content (%)
Implants 95.1 0.05 493 27 1.749 0.782 20.149 7.614 0.286 0.062 54.21 0.91 91.5 0.9
Human cornea >87 540 3e13 3.81 0.40 65.1 78
Fig. 1. Slit lamp biomicroscopy images of the corneas of all 10 patients at 4 years after grafting with a biosynthetic implant.
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months post-operation, there was no signiﬁcant change in corneal
thickness from 1 to 4 years postoperatively in either patients with
biosynthetic implants or human donor corneas (p ¼ 0.92). Central
corneal thickness at four years was 358 101 mm in patients with
biosynthetic implants, 576 50 mm in patients with human donor
corneas, and 534 30 mm in healthy corneas. Biosynthetic corneas
were signiﬁcantly thinner than healthy corneas (p< 0.001), while
human donor corneas were signiﬁcantly thicker than healthy cor-
neas (p ¼ 0.046).
Detailed 3-dimensional topographical mapping of the nine
keratoconus patients’ corneas prior to surgery showed the typical
pattern of the disease, consisting of a severe paracentral promi-
nence (ectasia) surrounded by a ring of relative depression below
the best ﬁt sphere used to describe the shape of the cornea. After
surgery, ﬂattening of the cone was sustained to four years in all
patients. However, a high degree of surface irregularity was found.
This was most likely linked to tight overlying mattress sutures that
induced superﬁcial deformation/indentation of the non-rigid im-
plants, as the analyses also conﬁrmed that surface irregularities
adopted the hexagonal-shaped paracentral pattern of the tight
overlying sutures.
Indeed, apart from focal areas of haze that corresponded to the
hexagonal-shaped areas, the rest of the regenerated corneas
remained transparent over the four years. In contrast, the donor
corneas which received peripherally placed sutures did not show
central haze but instead had annular haze at the hostegraft inter-
face, which sometimes extended into the grafted area.
3.3. Immune compatibility
In biosynthetic implanted corneas, the sutures were removed
at 6.5 weeks (range: 4e7 weeks), after which prophylactic
immunosuppressive steroids were stopped. Over the four year
post-operative period, no episodes of rejection were observed.
The nine patients implanted with donor corneas received ste-
roids for 12 months and sutures were removed after a mean of
13 months (range: 12e18 months). One patient had a rejection
episode at one year that resolved after topical dexamethasone
treatment.
Large numbers of mature dendritic cells were present in the
central region of human donor corneas (Fig. 3B), but not in biosyn-
thetic implants (Fig. 3A) or healthy corneas (Fig. 3C). MainlyFig. 2. Anterior segment optical coherence tomography images of the same central cornea, f
biosynthetic implant in a 30 years old female appears stable over time (slight differences are
52 years old male exhibits wound compression due to the sutures, posterior donor-recipient
(arrows) that resolve after suture removal at one year. Right column, appearance of four heimmature dendritic cells were observed in both the biosynthetic
implants and healthy corneas. The density of dendritic cells (of each
type and total) in the patient and healthy volunteer groups at four
years is given in Fig. 3D. Total dendritic cell density in the human
donor cornea groupwas signiﬁcantly greater than in the biosynthetic
group (p¼ 0.012). When considering only mature dendritic cells, the
density in human donor corneas was signiﬁcantly increased relative
to biosynthetic or healthy corneas (p< 0.001), while density in the
biosynthetic and healthy groups did not differ (p> 0.05).
3.4. Active regeneration of corneal cells and nerves to restore
normal morphology
In vivo confocal microscopy showed that the regenerated
epithelium remained stratiﬁed through the four years post-
implantation, with proper density and morphology of the cell
layers (Fig. 4A), similar to human donor corneas and healthy con-
trols. At 4 years, the initially cell-free implants were populated by
stromal cells that had grown into the implants, but cell-free areas,
still remained (Fig. 4A marked with *; Fig. 5). Human donor corneas
had fewer stromal cells than healthy corneas, and additionally had
small particulate bodies and linear structures indicative of
apoptosis, whereas healthy controls had a dense, even distribution
of stromal cells. The posterior stromal and endothelial layers, which
were untouched during the lamellar surgery, remained healthy and
unaffected by the implant at four-years post-operation, as
conﬁrmed by histology (Fig. 5).
At 4 years post-operation, the nerves from the plexus lying
under the epithelium (subbasal nerves) in the human donor cornea
group had reached the central corneal region to varying degrees
(Fig. 4A, bottom row). However, they were generally sparse, highly
branched and abnormally tortuous. In corneas that received
biosynthetic implants, the regenerated nerves followed straighter,
parallel paths as described for healthy corneas [22], although the
nerve ﬁbres in healthy corneas were thicker and more densely
packed.
To test the functional response of the regenerated nerves, cen-
tral corneal touch sensitivity was assessed by contact esthesiom-
etry in the patients’ operated eyes and their contralateral
unoperated eyes, which served as controls (Fig. 4B). Two-way
ANOVA analysis revealed that touch sensitivity in corneas
implanted with human donor and biosynthetic tissue was signiﬁ-
cantly reduced (p< 0.001, both groups) relative to unoperated eyes,ollowed over 4 years in biosynthetic and human donor implanted corneas. Left column,
due to slightly different location of sections). Centre column, human donor cornea in a
edges mismatch, posterior graft protrusion (arrowhead) and stromal compression lines
althy corneas aged 16e64 years.
Fig. 3. In vivo confocal microscopic images of inﬂammatory dendritic cells at four years post-operation in regenerated neo-corneas compared to donor cornea grafted and normal,
healthy eyes. (A) Few immature dendritic cells (white arrows) are seen in the basal epithelium of a regenerated neo-cornea. (B) Mature (black arrows) and immature (white arrows)
dendritic cells in the central basal epithelial region of a cornea grafted with donor tissue, localized to the subbasal nerve plexus. (C) Mature (black arrow) and immature (white
arrow) dendritic cells in the normal corneal basal epithelium. Scale bars, 100 mm. (D) Density of dendritic cells in the subbasal epithelium of the central cornea in healthy and 4 year
post-operation groups. Data are given as median, 25th and 75th percentiles. M¼mature dendritic cells (cell bodies with dendrites), I¼ immature dendritic cells (cell bodies only),
T¼ total dendritic cells (matureþ immature). The dashed line indicates the previously reported mean value of 34 3 cells/mm2 for the central corneal dendritic cell density in
healthy eyes [16].
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Touch sensitivity in corneas with biosynthetic implants, however,
was signiﬁcantly better than in human donor corneas (p¼ 0.04).
Histology sections through a regenerated neo-cornea showed a
normal, healthy corneal architecture, with a stratiﬁed non-
keratinized epithelium, lamellarly arranged stroma and a layer of
endothelium (Fig. 5A). However, there was a cell-free region in the
centre of the stroma, which represents the part of the implant that
had not yet been remodelled. In areas where the remodelling is
more advanced, the implant had blended seamlessly into the
stroma (Fig. 5B). The histology, coupled with the in vivo confocal
images, supports the contention that active regeneration was still
on-going at four years post-operation.3.5. Corneal visual acuity
Distance-corrected visual acuity was achieved in the biosyn-
thetic group by use of custom-ﬁtted hard contact lenses to regu-
larize an uneven corneal surface, which were tolerated by patients
after surgery but not before [8]. In the human donor group,
distance-corrected visual acuity was measured with spectacles. At
four years, distance-corrected visual acuity was 20/54 and 20/36 in
the biosynthetic and human donor groups, respectively. In terms of
vision improvement from the preoperative level, the biosynthetic
group had a mean gain of 5.6 Snellen lines, while the human donor
group had a mean gain of 9.9 Snellen lines at 4 years post-
operatively.
Fig. 4. Typical in vivo confocal microscopic appearance of four-year post-operation and unoperated normal corneas (A) and corneal sensitivity to touch measured longitudinally (B).
(A) Top row: similar cell morphology is apparent in the regenerated epithelium in operated groups. Middle row: stromal keratocytes (black arrowheads) migrate into the cell-free
scaffold (asterisks), while human donor stroma is characterized by fewer keratocytes, linear reﬂective structures (white arrowheads) and particulate bodies (white arrows)
indicative of cell apoptosis. By comparison, the healthy stroma contains a dense, regular distribution of keratocytes. Bottom row: subbasal epithelial nerves in biosynthetic corneas
adopted linear, parallel arrangements (black arrows). An absence of Bowman’s layer in implants renders keratocytes visible in the same plane as subbasal nerves. In human donor
corneas, nerves adopted tortuous paths and dendritic cells were present along with nerves. Dense, parallel nerve architecture is present in the healthy cornea. (B) Epithelial nerve
functional testing by esthesiometry indicates hyposensitivity in both operated groups relative to normal corneas, but signiﬁcantly better sensitivity in biosynthetic implants relative
to human donor corneas (two-way ANOVA, p¼ 0.04). Scale bars, 100 mm.
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The biosynthetic implants that we fabricated as grafts were
optically transparent but signiﬁcantly weaker than the human
corneas. Nevertheless they were sufﬁciently robust for grafting.
Over four years, these cell-free implants promoted regeneration of
corneal tissues and nerves. The regenerated neo-tissues and nerveshad stably and seamlessly integrated into the patients' own corneas
without requiring immunosuppression beyond a short course of
prophylactic steroids. In donor corneal grafts, however, 12 months
of immunosuppressive steroids was standard therapy. Even then,
one rejection episode out of 9 grafts was observed at one year,
corresponding to 11% graft rejection and consistent with the re-
ported rate of 10% within the ﬁrst two years post-operation in
Fig. 5. (A) Haematoxylineeosin stained histologic section of a regenerated neo-cornea removed after 4 years when the patient was regrafted, showing a normal corneal
morphology with stratiﬁed epithelium (ep), lamellarly arranged stroma (s) and endothelium (en) that was left intact during the implantation. Part of the recombinant human
collagen implant (i) is still present, showing a slow but active remodelling process over time. (B) Higher magniﬁcation showing an area of the cornea where remodelling is more
advanced and the implant (i) is seamlessly blending into the stroma (s). ep, epithelium. Scale bars, 100 mm.
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had been stimulated to regenerate using cell-free biosynthetic
implants. Rejection reactions, although less frequent in lamellar
than in penetrating grafts, nevertheless still occur [23,24]. Reports
to date imply that the immune reactions in allografts are directed
against foreign cells [25,26], suggesting that the cell-free biosyn-
thetic implants may inherently avoid rejection.
At the microscopic level, we found mature antigen presenting
dendritic cells in the donor cornea grafted eyes. Dendritic cells
serve as immune sentinels, regulating the immunogenicity of the
organ, and determine whether a graft is tolerated or rejected [15].
In the healthy cornea, there are very few mature dendritic cells
present centrally and immature cells are present in low numbers
[16,17]. A proinﬂammatory environment such as human donor
tissue transplantation is needed for their maturation [17,27].
Interestingly, while the donor corneas contained a high density of
both immature and mature dendritic cells, only a few, sparsely
distributed dendritic cells were observed in the regenerated neo-
corneas. Biosynthetic implants, free of foreign-source cells and
antigens, appear to avoid dendritic cell activation and/or recruit-
ment, despite the early cessation of topical anti-inﬂammatory
treatment.
Topographical mapping showed that the implants retained their
shape over time, indicating stability. The presence of haze, thinning
and shape irregularities, however, shows that the overall clinical
outcome is dependent upon both the implant properties and the
surgical method, i.e. suturing technique used for implantation.
Beyond the early thinning caused by the presence of the tight su-
turespressing into the implant, therewas no change in the thickness
or shape of the corneas receiving biosynthetic implants. The use of
peripherally located sutures in the human donor implants accoun-
ted for the lack of central haze or thinning. A more resilient opticalsurface that maintains its shape despite suturing would thus be
desirable. Hence, we have now signiﬁcantly increased and rein-
forced the solids content of our next generation implants and, with
it, mechanical strength and the ability to resist suturing-caused
surface indentation caused suturing or neovascularization [28].
A functioning stratiﬁed epithelium that had regenerated
remained stable in the long term in the biosynthetic implants.
Corneal nerves are known to serve critical roles in regulation of the
tear ﬁlm and epithelial barrier through the secretion of neuro-
trophic factors [22]. Here, we show that the subbasal epithelial
nerves had re-grown into the central corneal region of biosynthetic
implants, and had adopted a regular, parallel-running architecture
and have given rise to a blink reﬂex to touch. The nerve architecture
and sensitivity of biosynthetic implants more closely resembled the
healthy cornea than human donor tissue. The patients continued to
improve in their blink reﬂex testing sensitivity over the four years.
In vivo confocal microscopy showed that even at four years after
implantation, the patients’ own stromal cells continued to actively
migrate into the initially cell-free biosynthetic implants.
Conversely, a sparse stromal cell population and cell death was
apparent in human donor tissue. Histology of a regenerated neo-
cornea showed a normal corneal morphology with a stratiﬁed
epithelium and lamellarly arranged stroma, albeit with implant
tissue that had not been completely remodelled yet. In summary,
the RHCIII implant possesses the ability to guide proper morpho-
logical and functional regeneration of corneal tissue.
This study conﬁrms the long-term safety and efﬁcacy for the use
of collagen-based biomaterials in regenerating a human tissue. In
addition to its use in biosynthetic corneal implants, our work, and
that of others, has shown the adaptability and modularity of
collagen as a basic building block for multiple tissue types. With
adjustments, such as changing the method of fabrication to plastic
P. Fagerholm et al. / Biomaterials 35 (2014) 2420e2427 2427compression or electrospinning, or adding other components such
as chondroitin sulphate, chitosan, adhesion ligands or growth fac-
tors, we have developed regeneration templates for other organ
systems [29e32]. A better understanding of the role that the
extracellular environment plays in the body’s endogenous repair
responses will allow formore optimized biomaterial design tomeet
the requirements for a wide variety of regenerative medicine ap-
plications that may soon ﬁnd their way into the clinic.
5. Conclusion
We have shown that cell-free, biosynthetic implants promoted
endogenous regeneration of corneal tissue and nerves that were
stable over four years, without any rejection episodes and in the
absence of immunosuppression. In terms of aesthetic appearance,
resolution of the initial blinding pathology and potential for
restoration of vision in the long term, the present study shows that
with further development, biosynthetic implants that facilitate
endogenous regeneration may be viable long-term options that
could one day supplement the supply of human donor tissue for
surgical treatment of blinding conditions of the cornea.
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